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ABSTRACT
Background Compliance with continuous positive
airway pressure (CPAP) therapy is essential in patients
with obstructive sleep apnoea (OSA), but adequate
control is not always possible. This is clinically important
because CPAP can reverse the morbidity and mortality
associated with OSA. Telemedicine, with support
provided via a web platform and video conferences,
could represent a cost-effective alternative to standard
care management.
Aim To assess the telemedicine impact on treatment
compliance, cost-effectiveness and improvement in
quality of life (QoL) when compared with traditional
face-to-face follow-up.
Methods A randomised controlled trial was performed
to compare a telemedicine-based CPAP follow-up strategy
with standard face-to-face management. Consecutive
OSA patients requiring CPAP treatment, with sufﬁcient
internet skills and who agreed to participate, were
enrolled. They were followed-up at 1, 3 and 6 months
and answered surveys about sleep, CPAP side effects and
lifestyle. We compared CPAP compliance, cost-
effectiveness and QoL between the beginning and the
end of the study. A Bayesian cost-effectiveness analysis
with non-informative priors was performed.
Results We randomised 139 patients. At 6 months, we
found similar levels of CPAP compliance, and improved
daytime sleepiness, QoL, side effects and degree of
satisfaction in both groups. Despite requiring more visits,
the telemedicine group was more cost-effective: costs were
lower and differences in effectiveness were not relevant.
Conclusions A telemedicine-based strategy for the
follow-up of CPAP treatment in patients with OSA was as
effective as standard hospital-based care in terms of CPAP
compliance and symptom improvement, with comparable
side effects and satisfaction rates. The telemedicine-based
strategy had lower total costs due to savings on transport
and less lost productivity (indirect costs).
Trial register number NCT01716676.
INTRODUCTION
Obstructive sleep apnoea (OSA) is a common con-
dition that causes signiﬁcant morbidity and mortal-
ity and increased use of healthcare resources.1 2
Currently, improved case detection and the result-
ing higher healthcare demands have not been
accompanied by any real improvement in OSA
management. In addition, health resources assigned
to OSA and its treatment have been found to be
inadequate.3 Continuous positive airway pressure
(CPAP) is the optimal treatment for OSA.
Nevertheless, many patients fail to use CPAP
adequately; this is clinically relevant since increased
adherence reduces symptoms and comorbidities.4
Optimising adherence is therefore an essential
Key messages
What is the key question?
▸ What is the clinical and economic impact of a
telemedicine-based approach for the follow-up
of continuous positive airway pressure (CPAP)
treatment in patients with obstructive sleep
apnoea (OSA)?
What is the bottom line?
▸ Adherence to CPAP treatment is essential for
treatment success; telemedicine could provide a
cost-effective alternative to the standard
face-to-face approach of CPAP follow-up.
Why read on?
▸ This multicentre randomised controlled trial
provides evidence that a telemedicine-based
strategy for the CPAP follow-up of OSA
patients is as effective as the face-to-face
approach but has lower cost for society.
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aspect of patient management and different educational and
technical measures have been proposed.5 6–10 However,
adequate provision of such support is not always possible, and
overloaded sleep centres can be hard-pressed, especially after
recent healthcare budget cuts. Therefore, alternative and cost-
effective approaches are urgently needed to improve OSA man-
agement and to promote CPAP compliance. A possible approach
is telemedicine, deﬁned here as the use of information and com-
munication technology (ICT) to provide clinical care for a
patient at a distance.11 However, conﬂicting results have been
found12 13 and the economic impact of telemedicine on OSA
management is still unclear.14–18 We conducted a multicentre
randomised controlled trial (RCT) to evaluate the efﬁcacy of a
new telemedicine-based strategy for OSA patients under CPAP
treatment. Speciﬁcally, we assessed its impact on treatment com-
pliance, sleepiness, quality of life (QoL) and cost-effectiveness
when compared with traditional face-to-face follow-up.
METHODS
Study design
This RCT was approved by the ethics committees of the eight
participating hospitals in Spain. All patients provided informed
consent prior to participation. Patients were randomly assigned
to either standard face-to-face follow-up (control group) or to
telemedicine-based follow-up for 6 months (ﬁgure 1).
Population
Participants were prospectively enrolled between December
2011 and December 2013. In accordance with Spanish health
service guidelines, all enrolled patients were classiﬁed as requir-
ing CPAP treatment after an overnight study.19 Exclusion criteria
were as follows: severe sleepiness, severe nasal obstruction,
pregnancy, psychiatric disease, dangerous employment, clinical
instability and current or previous treatment for OSA. We
excluded patients who lacked sufﬁcient internet skills or refused
to participate in the study. Both groups were equipped with con-
ventional masks and received the same instructions regarding
initial CPAP use.
Procedures
Clinical evaluation and follow-up
Patients’ baseline characteristics were collected at the initial visit.
In addition, EuroQol-5D, the Epworth Sleepiness Scale (ESS),
the Functional Outcomes of Sleep Questionnaire (FOSQ) and
the Quebec Sleep Questionnaire (QSQ) were administered. At
6 months, data on CPAP compliance, satisfaction and side
effects were gathered and questionnaires repeated. Data related
to costs were collected for the entire process. At intermediate
visits (months 1 and 3), additional information was recorded
regarding side effects, lifestyle changes and actions taken.
Sleep studies
All patients underwent a sleep study which was scored manually
by trained personnel.19 Optimal CPAP pressure was titrated by
an auto CPAP device to obtain a ﬁxed pressure.20 Tests were
repeated if patients claimed to sleep less than 4 h, or when less
than 5 h of recording were available.
Randomisation
Participants who completed the baseline visit were randomly
assigned (1:1) to the control or telemedicine group.
Randomisation was at an individual level without restriction
Figure 1 Study ﬂowchart. The two
groups received CPAP treatment
follow-up via two different strategies:
conventional follow-up, which
consisted of face-to-face hospital visits
(the control group), and
telemedicine-based follow-up, using a
website and televisits (the telemedicine
group). The main outcomes were CPAP
compliance, QoL and
cost-effectiveness. During the
intermediate visits, only questionnaires
were administered and some corrective
actions were recommended if required.
CPAP, continuous positive airway
pressure; ITT, intention-to-treat; OSA,
obstructive sleep apnoea; PP, per
protocol; QALY, quality-adjusted life
year; QoL, quality of life.
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(ie, no blocking) and was completely automated by use of an
unseen random number function embedded in the data collec-
tion website code. There was no clinician involvement at this
stage, and the software only revealed the allocation group when
an investigator provided the data of a fully eligible patient, thus
guaranteeing concealment of the randomisation sequence.
Telemedicine-based follow-up
Patients randomised to the telemedicine group received their
follow-up at home supported by a website developed for this
study, where they could ﬁnd information about OSA and CPAP
therapy, and a biweekly six-item questionnaire about their
status, physical activity, sleep time, CPAP use and treatment side
effects. Each centre’s staff monitored questionnaire answers and
communicated with patients through the website messaging tool
to solve treatment-related problems. To participate, patients
only required an internet-connected device with a microphone
and webcam. Televisits via video conference were undertaken at
months 1 and 3. We used Skype due to its availability, ease of
use and good performance.21 Patients automatically received a
conﬁrmation email indicating the date and time of their
appointment. Extra televisits or hospital visits were scheduled as
necessary.
Hospital-based follow-up
As shown in ﬁgure 1, patients randomised to the control group
had the same follow-up schedule as the telemedicine group, but
attended the hospital. Speciﬁcally, they received standard
face-to-face follow-up with visits at months 1, 3 and 6, and
extra visits if needed.
Outcomes
The primary outcomes were: (1) CPAP compliance; and (2) the
cost-effectiveness of the two follow-up strategies, compared
using quality-adjusted life years (QALYs) as a measure of effect-
iveness. QALYs were estimated from the EQ-5D tariffs.22–24
Secondary outcomes included questionnaire changes from base-
line, CPAP treatment side effects and patient satisfaction.
Cost analysis
We adopted a societal perspective in the cost-effectiveness ana-
lysis, where both direct and indirect costs were considered but
immaterial costs were not taken into account. Direct health
costs were associated with the use of healthcare resources, such
as medical and nursing personnel salaries and all costs related to
follow-up. These included material costs such as masks, humidi-
ﬁers and medications used by patients, as well as the costs of
extra visits to respiratory physicians, other specialists, general
practitioners, nurses and emergency services. Two types of extra
visits were deﬁned: OSA-related and non-OSA-related. Unit
costs were provided by the administrative departments of one of
the participating hospitals.
Direct non-health costs referred to the travel expenses
incurred by patients when attending hospital. Indirect costs
referred to the opportunity costs of lost productivity and work
due to follow-up visits; we considered time lost due to both
hospital visits and video conferences. The ﬁnal visit after
6 months was a face-to-face visit for both groups; this was
included in the protocol to allow comparison with the data
obtained at the ﬁrst visit. However, in normal practice this
face-to-face visit would not be needed for the telemedicine
group. For this reason, the costs of transport to the 6-month
visit were not considered in the cost analysis for the
telemedicine group, and we assumed indirect costs similar to
those for the intermediate visits.
The total costs were evaluated against the QALYs through a
Bayesian cost-effectiveness analysis. Other complementary cost-
effectiveness analyses were assessed, taking into account changes
in the ESS and CPAP treatment compliance.
Statistical analysis
We considered two analysis populations for this trial: an
intention-to-treat (ITT) population (all randomised patients)
and a per protocol (PP) population (all randomisation patients
who ﬁnished the study). The planned sample size was based on
the assumptions that 85% of the patients who were randomly
assigned to treatment would meet the above deﬁnition of a PP
sample for the non-inferiority test. The study was based on the
assumption that the average compliance without intervention
would be 4 h/day (SD 1.8). According to a one-sided type I
error of 0.025 and 80% power to verify that CPAP compliance
in the telemedicine group was not less than 1 h/day (SD 2), and
assuming a 10% drop-out rate, the sample size was 60 patients
in each group.
We reported means and SD for continuous variables with
normal distribution and medians (1st quartile–3rd quartile) for
those with non-normal distribution, and compared them using
the t test or the non-parametric Mann–Whitney test, respect-
ively. Categorical variables are presented as number of patients
(%) and were compared using the χ2 test or Fisher exact test.
Conventional regression imputation techniques were used to
estimate values for patients without valid CPAP use measure-
ments at 6 months, assuming that missing data were missing at
random. For the 16 patients with missing CPAP use at 6 months
(eight in the control group and eight in the telemedicine group),
we generated values based on sex, age, baseline snoring, wit-
nessed apnoeas, choking episodes, nocturia, daytime sleepiness,
non-restorative sleep, daytime fatigue, drowsiness during
driving, nasal problems and ESS score, using stochastic regres-
sion imputations by a linear regression method.
Table 1 Baseline characteristics
All patients
(N=139)
Telemedicine
(N=69)
Control
(N=70)
Men 120 (86%) 59 (85%) 61 (87%)
Age (years) 49.0 (10.1) 51.0 (8.9) 47.0 (10.9)
BMI (kg/m2) 33.2 (7.8) 32.8 (7.3) 33.6 (8.3)
Epworth Sleepiness
Scale
10.7 (4.7) 10.5 (4.6) 10.8 (4.8)
Cardiovascular disease 18 (13%) 11 (16%) 7 (10%)
Depression 20 (14%) 13 (19%) 7 (10%)
Daytime fatigue 97 (70%) 49 (71%) 48 (69%)
Drowsy driving 73 (52%) 36 (52%) 37 (53%)
Nasal problems 89 (64%) 46 (67%) 43 (62%)
Apnea-Hypopnea Index
(event/h)
49 (35–46) 45 (35–70) 52 (35–62)
Oxygen Desaturation
Index (%)
46 (27–67) 43 (27–67) 48 (27–67)
CT90 (%) 12.0 (3–31) 13.0 (3–30) 11.5 (3–31)
CPAP pressure
(cm H2O)
9 (8–11) 9 (8–11) 9 (8–10)
Intention-to-treat population.
Data are shown as mean (SD), median (1st quartile–3rd quartile) or number of
patients (%).
BMI, body mass index; CPAP continuous positive airway pressure.
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The non-inferiority analyses were based on the PP sample
according to International Committee for Harmonization (ICH)
E9 guidelines.25 Non-inferiority of the telemedicine group com-
pared with control was assessed by a one-sided 97.5% CI for the
point estimate of the difference between the two groups, calcu-
lated by adequacy of CPAP adherence, using two-sample t tests.
Overall efﬁcacy analyses were conducted using the ITTsample.
We evaluated treatment effects by two-sided tests with a signiﬁ-
cance level of α=0.05. Multiple linear regression analysis was
performed to assess the relationship between potential predictive
factors and CPAP compliance (dependent variable). Details about
variable selection are provided in online supplementary material.
We compared continuous efﬁcacy measures between groups
using analysis of covariance (ANCOVA) models with adjustment
for baseline variables and centre. We analysed categorical efﬁcacy
and safety measures by using logistic regression models.
All analyses were performed with IBM SPSS Statistics V.20.0.
Cost-effectiveness analysis
The cost-effectiveness analysis was carried out in a Bayesian
framework.26 27 Considering the asymmetry in the cost distribu-
tion and the correlation between effectiveness and cost, we
assumed a multivariate normal distribution for the effectiveness
and the log-transformed costs. In a Bayesian analysis, the prior
distributions for the parameters of the model should be deﬁned.
We used non-informative priors to let the sample data control the
posterior distribution. We estimated posterior distributions using
Markov Chain Monte Carlo methods.28 The expected mean
effectiveness and costs, and 95% Bayesian credible interval were
then estimated from the posterior distributions. Moreover, we
assessed the incremental effectiveness and cost, and the probabil-
ity that telemedicine would be more effective or cheaper than
control. To illustrate the results, we used the cost-effectiveness
plane, where the joint posterior distribution of the incremental
effectiveness and costs are displayed in an x-y plot, and the cost-
effectiveness acceptability curve (CEAC), where the probability
of preference for telemedicine is displayed as a function of the
willingness to pay for a QALY.29 Furthermore, for certain combi-
nations between groups, we assessed the incremental effective-
ness, incremental cost and incremental net beneﬁt.
RESULTS
Of the 240 patients screened, 139 were randomised and 123
(88%) completed the study (ﬁgure 1). Data are reported on an
Table 2 Comparison of change from baseline in QoL, ESS and BMI between the telemedicine and control groups
Control Telemedicine LS mean*†
difference
(telemedicine
minus control)
95% CI for the
difference
p Value
Baseline
Mean (SD) (N=70)
Follow-up
Mean (SD) (N=64)
Baseline
Mean (SD) (N=69)
Follow-up
Mean (SD) (N=64) Lower Upper
EuroQol
EQ-5D 0.84 (0.18) 0.88 (0.20) 0.78 (0.23) 0.82 (0.19) −0.03 −0.09 0.03 0.38
EQ VAS 6.43 (2.07) 7.36 (1.88) 6.74 (1.69) 6.80 (2.18) −0.48 −1.10 0.15 0.13
Quebec
Hypersomnolence 4.58 (1.67) 5.95 (1.22) 4.56 (1.56) 5.81 (1.30) −0.05 −0.40 0.31 0.80
Diurnal symptoms 4.72 (1.57) 5.92 (1.12) 4.35 (1.60) 5.68 (1.40) −0.05 −0.41 0.32 0.81
Nocturnal symptoms 4.34 (1.47) 5.80 (1.34) 4.38 (1.29) 5.50 (1.33) −0.20 −0.61 0.21 0.33
Emotions 5.01 (1.48) 5.91 (1.39) 4.69 (1.41) 5.61 (1.38) −0.07 −0.45 0.32 0.74
Social interactions 4.57 (1.61) 6.14 (1.09) 4.74 (1.47) 5.84 (1.24) −0.24 −0.58 0.09 0.16
FOSQ 15.52 (3.21) 18.01 (2.97) 15.21 (3.41) 16.90 (3.94) −0.89 −1.70 −0.08 0.031
ESS 10.81 (4.82) 5.89 (3.51) 10.55 (4.62) 6.52 (4.14) 0.78 −0.40 1.95 0.19
BMI (kg/m2) 33.55 (8.33) 32.96 (8.19) 32.82 (7.32) 32.38 (7.37) 0.23 −0.53 0.99 0.55
Bold indicates significant p values.
*Analysis is based on an ANCOVA model for change from baseline in the adherence to continuous positive airway pressure (CPAP) treatment variables as response and with treatment
group as a factor along with baseline adherence to CPAP treatment variables as covariates.
†LS mean: least square mean for the change from baseline in the adherence to CPAP treatment variables in the ANCOVA model.
ANCOVA, analysis of covariance; BMI, body mass index; ESS, Epworth Sleepiness Scale; EQ, EuroQol; FOSQ, Functional Outcomes of Sleep Questionnaire; Quebec, Quebec Sleep
Questionnaire; QoL, quality of life; VAS, visual analogue scale.
Table 3 Comparison of typical OSA symptoms between the telemedicine and control groups
Control Telemedicine
OR*
(control group data
were reference values)
95% CI for the
OR
p Value
Baseline
N (%) (N=70)
Follow-up
N (%) (N=64)
Baseline
N (%) (N=69)
Follow-up
N(%) (N=64) Lower Upper
Snoring 65 (96) 12 (19) 68 (100) 14 (22) 1.13 0.46 2.78 0.78
Witnessed apnoeas 62 (97) 12 (19) 56 (88) 12 (19) 1.08 0.43 2.71 0.88
Daytime fatigue 48 (69) 14 (22) 49 (71) 21 (33) 1.85 0.82 4.20 0.14
Nocturia 39 (56) 17 (27) 44 (64) 15 (23) 0.74 0.31 1.74 0.48
Drowsy driving 42 (60) 15 (23) 39 (57) 12 (19) 0.82 0.33 2.01 0.66
*Estimate of the OR comparing telemedicine versus standard (standard being the reference group) follow-up derived using the logistic regression model for the typical OSA symptom
variables as response and with treatment group as a factor along with baseline typical OSA symptom variables as covariates.
OSA, obstructive sleep apnoea.
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ITT basis unless otherwise stated. Both groups had similar base-
line characteristics (table 1), except for lower mean age in the
control group.
CPAP adherence
Mean CPAP use was 4.2±2.0 h/day in the control group and
4.4±2.0 h/day in the telemedicine group (p=0.827). When
using the accepted deﬁnition of adequate adherence (>4 h/day),
57% of controls had adequate compliance compared with 65%
of the telemedicine group (p=0.329).
On bivariate analysis, several variables were signiﬁcantly asso-
ciated with CPAP compliance (see online supplementary table
S1). Among these variables, in the multivariate analysis CPAP
compliance was signiﬁcantly inﬂuenced by age and self-reported
daytime fatigue at the end of the study.
In the non-inferiority analysis, using the PP sample the point
estimate of the difference in CPAP compliance (telemedicine
minus control) was 0.04. The lower bound of the one-sided
97.5% CI for the point estimate was −0.72 for the PP sample,
which exceeded the previously speciﬁed −1 margin and met the
criteria for non-inferiority (see online supplementary ﬁgure S1).
Clinical outcomes
As shown in table 2, we found general improvements in QoL
and sleepiness (ESS) after 6 months of CPAP treatment, but
there were no signiﬁcant differences in change from baseline
between the telemedicine and control groups, except for FOSQ
(−0.89; 95% CI −1.70 to −0.08; p=0.031). There was no
change in body mass index (BMI) in either group. Similar
reductions were seen in the most common OSA symptoms
(snoring, witnessed apnoeas, nocturia) in both groups after
CPAP treatment (table 3). The side effects of CPAP treatment
were comparable between the two groups at the end of the
study (see online supplementary table S2). The two groups
reported similar degrees of satisfaction with the follow-up pro-
cedures (see online supplementary tables S3 and S4).
Resource use and cost analysis
Table 4 shows the average use of resources and costs of both
follow-up strategies. There were no signiﬁcant differences in the
average lengths of follow-up visits or mask changes. The tele-
medicine group required more extra visits: 16.7% and 28.3% of
these patients visited a physician or a nurse, respectively, during
the 6-month treatment period, compared to rates of 7.9% and
9.5% in the control group, with a signiﬁcant difference found
for nurse visits. Visits to general practitioners and emergency
services were more frequent in the telemedicine group, although
the differences were not statistically signiﬁcant. The number of
visits to general practitioners was lower when only OSA-related
visits were considered (falling from 28 to 12 for the control
group and from 40 to 9 for the telemedicine group). Only one
visit to the emergency service was OSA related. The main differ-
ences between groups concerned the time required for travelling
to the hospital and the missed work due to face-to-face visits.
Cost-effectiveness analysis
Table 5 summarises the cost-effectiveness analysis. The mean total
costs were €180.4 and €168.4 for the control and telemedicine
Table 4 Cost analysis
Time or use* Cost
Control Telemedicine p Value† Control Telemedicine p Value†
Follow-up visit time 37.53 (9.64) 38.97 (12.04) 0.686 35.59 (9.15) 35.58 (10.20) 0.840
Mask changes 32 (39.7%) 19 (30%) 0.158 25.40 (34.63) 15.83 (25.20) 0.158
Extra visits (physicians) 7 (7.9%) 11 (16.7%) 0.149 16.44 (65.71) 27.13 (63.86) 0.149
Extra visits (nurses) 10 (9.5%) 24 (28.3%) 0.010 0.66 (2.27) 1.48 (2.98) 0.012
GP visits 28 (23.8%) 40 (35%) 0.261 20.83 (48.22) 27.33 (52.12) 0.215
Emergency visits 3 (3.2%) 6 (6.7%) 0.378 5.32 (31.30) 11.18 (44.63) 0.371
Medications added 16 (25.4%) 19 (31.7%) 0.443 9.12 (33.01) 4.70 (14.27) 0.604
Travelling time to the hospital 23.30 (16.48) 8.64 (8.42) <0.001 15.26 (10.11) 7.02 (7.05) <0.001
Time out of work 55.03 (53.05) 21.12 (21.21) <0.001 47.00 (48.19) 34.30 (35.42) 0.240
Bold indicates significant p values.
*Mean and SD for time variables. For other variables, number of cases and % of the sample that used this resource.
†Groups compared by using the Mann-Whitney test.
GP, general practitioner.
Table 5 Cost-effectiveness analysis
Control Telemedicine Difference
Mean (SD) 95% CI Mean (SD) 95% CI Mean (SD) 95% CI
Cost (€) 180.4 (17.01) (151.3 to 218.0) 168.4 (19.65) (135.6 to 212.8) −11.99 (25.98) (−62.33 to 40.99)
SAHS-related cost (€) 150.9 (13.14) (128.1 to 180.1) 114.5 (12.08) (94.13 to 141.5) −36.35 (17.87) (−36.15 to −1.35)
Effectiveness
QALYs 0.0120 (0.0169) (−0.0211 to 0.0451) 0.0108 (0.0182) (−0.0250 to 0.0467) −0.0012 (0.0248) (−0.0500 to 0.0474)
Epworth 5.079 (0.5323) (4.034 to 6.124) 3.932 (0.5381) (2.869 to 4.992) −1.147 (0.7552) (−2.643 to 0.3317)
CPAP use (h) 4.179 (0.2752) (3.633 to 4.717) 4.416 (0.2583) (3.911 to 4.922) 0.2377 (0.377) (−0.5009 to 0.9699)
*Mean and SD for time variables. For other variables, number of cases and % of the sample that used this resource.
CPAP, continuous positive airway pressure; QALYs, quality-adjusted life years; SAHS, sleep apnoea-hypopnoea syndrome.
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groups, respectively. The estimated probability that telemedicine
would be cheaper than control was 68.8%. When only
OSA-related visits and drugs were considered, the estimated cost
for the control group was €150.9 and €114.5 for the telemedicine
group; this also increased the probability to 97.9%. The efﬁcacy
measure (QALYs) was lower on average for the telemedicine group
compared with the control group, although the difference was not
statistically signiﬁcant. The posterior distribution of the incremen-
tal effectiveness and incremental cost are showed in ﬁgure 2.
Figure 3 shows the CEAC. Since the telemedicine-based strategy
was cheaper than the hospital-based follow-up, it was preferable in
situations with low willingness to pay. At a standard
willingness-to-pay threshold of €20 000–30 000 per QALY, the
two procedures were equally cost-effective. CPAP compliance and
ESS improvements were considered alternative measures of effect-
iveness, but neither resulted in statistically relevant differences.
DISCUSSION
In this multicentre RCT, we compared a new telemedicine-based
follow-up strategy for OSA against standard face-to-face
follow-up over a 6-month treatment period. Although the study
groups achieved similar levels of CPAP use and clinical
outcomes, probably due to the low possibility of further
improvement in our setting, where levels of compliance are gen-
erally high,30 analyses showed telemedicine to be more cost-
effective, with travel costs and lost work time being the most
important sources of savings. Interestingly, the telemedicine
group made more extra visits than the face-to-face group, but
most of them were non-OSA-related. This may be explained by
the fact that telemedicine improved the communication between
professionals and patients, thereby increasing the detection of
non-OSA-related problems.
CPAP is the optimal treatment for OSA,31 but adherence fails
in some subjects. After analysing the relationship between com-
pliance and effects on symptoms in 30 articles (2047 partici-
pants), a 2014 Cochrane review emphasised the need for new
strategies that promote CPAP compliance and assessment of
their cost-effectiveness.32 Our study analysed these two aspects
(adherence to treatment and cost-effectiveness) in a novel
telemedicine-based approach for CPAP follow-up.
The application of ICT is increasing in clinical practice for
different diseases but prudence is required, especially after some
recent negative results.12 13 Some authors have highlighted the
need for a better understanding of the factors that predict
Figure 2 Cost-effectiveness
acceptability plane. A scatterplot of
the posterior cost and effectiveness
differences. Grey points represent
OSA-related costs and black points
represent total costs. OSA, obstructive
sleep apnoea; SAHS, sleep
apnoea-hypopnoea syndrome.
Figure 3 Cost-effectiveness
acceptability curve showing the
cost-effectiveness probabilities for
telemedicine-based follow-up by
different degrees of willingness to pay
for QALYs. QALY, quality-adjusted life
year; SAHS, sleep apnoea-hypopnoea
syndrome.
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success in telemedicine programmes before they are widely
implemented, stressing the importance of appropriate patient
selection.33 In a previous study we demonstrated that an OSA
population could beneﬁt from a telemedicine-based manage-
ment approach.34
Diverse results have been found for telemedicine interven-
tions designed to improve CPAP compliance in OSA.14–18
Sparrow et al14 randomly assigned 250 patients starting CPAP
therapy either to a telephone-linked interactive voice-response
system or to an attention placebo control for 12 months.
Patients in the telemedicine group showed improvements but
result interpretation is limited due to generally low CPAP adher-
ence.14 Similar limitations were found in another RCT that
assessed the application of a CPAP wireless telemonitoring
system.15 Other telemedicine interventions, such as televisits,
improved CPAP adherence in a small group of non-compliant
OSA patients.16 Nevertheless, other studies have not found any
positive effects.17 18 In summary, the results vary widely, and
most studies were single-centre with low levels of CPAP compli-
ance and small sample sizes. Moreover, very few performed
cost-effectiveness analyses.
In a recent systematic review of the cost-effectiveness of tele-
medicine, the authors stated that, even though the use of this
technological approach has grown over the last 30 years, deci-
sions are still inﬂuenced by ﬁnancial constraints.35 As men-
tioned, Wilson and colleagues33 reached similar conclusions.
Therefore, the cost-beneﬁt ratio of telemedicine-based health
strategies has still to be established. The Bayesian cost-
effectiveness analysis used in this paper is well suited to this
scenario, where there are small differences in the effectiveness
of the proposed strategies; that is, where there is a non-
negligible probability of a very small value for the denominator
of the incremental cost-effectiveness ratio. In that situation, the
Bayesian model allows us to estimate the parameters of interest
by introducing a non-informative prior density.
In our analyses we identiﬁed as key factors the costs related to
patients’ transport to the hospital and missed work time.
Therefore, our telemedicine-based approach could be especially
advantageous if applied to the working population and to resi-
dents in medically underserved areas. It is also reasonable to
expect that this new management strategy could be suitable in
clinical settings or health systems that achieve lower compliance
levels with conventional follow-up. As it should be for any treat-
ment option, appropriate patient selection remains a key issue.
Also, speciﬁc training of the staff involved in long-distance
follow-up would be necessary for optimal implementation.
As recommended by major guidelines regarding the applica-
tion of cost-effectiveness analysis, we adopted the societal per-
spective where all costs are considered regardless of who pays.
However, from the healthcare payer perspective, the
telemedicine-based strategy would be more expensive than
face-to-face follow-up (mean total costs would be €126.6 and
€116.8, respectively), conﬁrming that the main savings are
related to patients’ transport to hospital and loss of productivity.
Although the economic analyses in this study were rigorous
and extensive, some limitations are worthy of note. We did not
consider the indirect hospital costs or the costs of the equip-
ment needed to connect to the website. In addition, it could be
argued that a signiﬁcant number of patients with OSA do not
have sufﬁcient computer expertise; in our study approximately
40% of screened patients lacked such skills. However, given
the current exponential growth of internet and mobile phone
use, this percentage is likely to decrease over the next few
years.
In this multicentre RCTwe compared standard hospital-based
CPAP follow-up with a novel telemedicine-based strategy. We
conclude that the telemedicine procedure was more cost-
effective due to savings related to transport and productivity
losses. Patient satisfaction and side effects were similar.
Therefore, telemedicine represents a cost-effective strategy to
support the routine clinical follow-up of OSA patients receiving
CPAP treatment. Moreover, we believe that a telemedicine-based
strategy could provide an excellent alternative approach when
adequate face-to-face consultations are impractical.
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